1. Introduction
===============

The deep sea is a vast and relatively untapped source of unique molecular, structural and biological diversity with less than 2% of marine natural products reported in literature \[[@B1-marinedrugs-13-02526],[@B2-marinedrugs-13-02526],[@B3-marinedrugs-13-02526]\]. Life in the deep sea requires its inhabitants to adapt their biochemical machinery to cope with extreme conditions, involving exposure to high hydrostatic pressures, variable temperatures and low oxygen and light. The extremophilic organisms may have the potential to induce primary and secondary metabolic pathways to give rise to structurally unique metabolites. The recent advancements in marine technologies have allowed accessing the deep sea and to detect microbial activities \[[@B4-marinedrugs-13-02526],[@B5-marinedrugs-13-02526]\], while screening of phylogenetically diverse and unique organisms from rare or extreme ecosystems in the deep ocean floor has been used to discover relevant bioactive metabolites. Deep sea derived natural products have emerged as a new frontier in drug discovery and development, leading to the identification of anti-tumor, anti-microtubule, anti-proliferative, photoprotective, antibiotic and anti-fouling compounds in the marine environment \[[@B6-marinedrugs-13-02526],[@B7-marinedrugs-13-02526],[@B8-marinedrugs-13-02526],[@B9-marinedrugs-13-02526],[@B10-marinedrugs-13-02526],[@B11-marinedrugs-13-02526],[@B12-marinedrugs-13-02526]\]. Despite the high scientific and commercial interest in the microbial ecology of these ecosystems, relatively little is known about the diversity of functional taxonomic groups of free-living microbes that occupy these niches as well as their biotechnological potential \[[@B13-marinedrugs-13-02526]\]. Fungi derived from deep water sediments have yielded an array of interesting new metabolites, including indole diketopiperazines, indole and quinazolinone alkaloids, sterigmatocystin derivatives, benzodiazepine alkaloids, polyketides, spiroditerpenoids, sesquiterpene quinones, sorbicillinoids, and trichoderones with strong bioactivities such as cytotoxic, antibiotic and antiviral effects.

In the course of our ongoing search for structurally unusual and bioactive secondary metabolites from deep sea derived microorganisms, a *Spiromastix* sp. fungus MCCC 3A00308 isolated from a sediment of South Atlantic at depth of 2869 m was examined chemically. Previously, a number of new depsidone-based spiromastixones A--O with potent antibacterial effects were isolated from the fermentation broth of this specimen \[[@B14-marinedrugs-13-02526]\]. Further examination of the minor components resulted in the isolation of 11 new diaryl derivatives, named spiromastols A--K (**1**--**11**) ([Figure 1](#marinedrugs-13-02526-f001){ref-type="fig"}). Herein, we report the isolation and structure elucidation of the new compounds and their antibacterial activities.

![Structures of spiromastols A--K (**1**--**11**).](marinedrugs-13-02526-g001){#marinedrugs-13-02526-f001}

2. Results and Discussion
=========================

Spiromastol A (**1**) was isolated as a colorless oil ([Figure 1](#marinedrugs-13-02526-f001){ref-type="fig"}). Its molecular formula was deduced as C~18~H~19~Cl~3~O~4~ on the basis of the HRESIMS (*m/z* 403.0272 \[M − H\]^−^) and NMR data, requiring eight degrees of unsaturation and containing three chlorine atoms. The IR absorption bands at 3408, 1651 and 1601 cm^−1^ suggested the presence of hydroxy and aromatic functionalities. The ^1^H NMR spectrum displayed three exchangeable protons (δ~H~ 10.00, 9.99 and 9.73), two aromatic singlets at δ~H~ 5.97 (1H, s, H-1) and 6.57 (1H, s, H-3′), and the alkyl protons for four methylene and two methyl groups. The ^13^C NMR spectrum exhibited a total of 18 carbon resonances, including 12 aromatic carbons for two phenyl moieties (rings A and B) and six alkyl carbons for two *n*-propyl groups, which were assigned by the COSY and HMBC correlations ([Figure 2](#marinedrugs-13-02526-f002){ref-type="fig"}). In regard to the substitution of the aromatic ring A, the HMBC interaction of H-1 with a *n*-propyl methylene (δ~C~ 35.6, C-7) allowed to assign the location of the *n*-propyl group vicinal to C-1 (δ~C~ 106.7). Additional HMBC interactions from H-1 to C-2 (δ~C~ 153.1), C-3 (δ~C~ 108.4), and C-5 (δ~C~ 114.8), and a weak correlation with C-4 (δ~C~ 150.3), H~2~-7 (δ~H~ 2.48, m) to C-1, C-5 and C-6 (δ~C~ 139.0), and a phenol proton at δ~H~ 10.00 (brs, OH-4) to C-3, C-4 and C-5 established a 3,5-disubstituted and 2,4-dioxygenated 6-propylphenyl segment, in which C-4 was hydroxylated. Similarly, the substitution of the aromatic ring B was established on the basis of the HMBC relationships. The observation of the HMBC interactions from the aromatic proton H-3′ to C-1′ (δ~C~ 132.7), C-2′ (δ~C~ 149.3), C-4′ (δ~C~ 151.5) and C-5′ (δ~C~ 110.4), the phenol proton at δ~H~ 9.73 (s, OH-2′) to C-1′, C-2′ and C-3′ (δ~C~ 102.7), and the other phenol proton at δ~H~ 9.99 (s, OH-4′) to C-3′, C-4′ and C-5′, in addition to the HMBC interactions of the second *n*-propyl protons, assigned a 5′-substituted and 1′-oxygenated 2′,4′-dihydroxy-6′-propylphenyl ring. Since two aromatic rings covered eight degrees of the molecular unsaturation, the connection of rings A and B was suggested through a C-C bond or an ether bond. The observation of NOE interaction between H-1 and OH-2′ ([Figure 2](#marinedrugs-13-02526-f002){ref-type="fig"}) assumed an ether linkage across C-2 and C-1′. Thus, the quaternary carbons C-3, C-5 and C-5′ were substituted by chlorine atoms.

![Key 2D NMR correlations of **1**, **7** and **9**.](marinedrugs-13-02526-g002){#marinedrugs-13-02526-f002}

The molecular formula of spiromastol B (**2**) was determined as C~18~H~18~Cl~4~O~4~ by the HRESIMS (*m/z* 436.9873 \[M − H\]^−^) and NMR data, indicating the presence of one more chlorine atom and the absence of a proton in comparison with those of **1**. The NMR data of **2** were very similar to those of **1**, with the exception of a quaternary carbon (δ~C~ 109.6, C-3′) of **2** to replace an aromatic methine of **1**. Comparison of the NMR data in association with the HMBC interactions, such as from H~2~-7 (δ~H~ 2.49, m) to C-1 (δ~C~ 106.8), C-5 (δ~C~ 115.4) and C-6 (δ~C~ 139.3), from the phenol proton OH-4 (δ~H~ 10.10, s) to C-3 (δ~C~ 108.9), C-4 (δ~C~ 150.5) and C-5, and from H-1 (δ~H~ 5.97, s) to C-2 (δ~C~ 152.9), C-3, C-4 and C-5, indicated both compounds sharing the partial structure of the aromatic ring A. Thus, the additional chlorine atom was placed in the aromatic ring B. The HMBC relationships of both phenol protons at δ~H~ 9.91 (s, OH-2′) and 9.86 (s, OH-4′) with the quaternary carbon C-3′, clarified the structure of **2** to be a 3′-chlorinated analogue of **1**.

Spiromastol C (**3**) has a molecular formula of C~19~H~20~Cl~4~O~4~ as determined by the HRESIMS data (*m/z* 451.0042 \[M − H\]^−^), containing a CH~2~ unit more than that of **2**. The similar NMR data with the exception of the presence of methoxy resonances whose protons (δ~H~ 3.83, s) correlated to C-2′ (δ~C~ 150.5) in the HMBC spectrum, clarified compound **3** to be a 2′-methoxy analogue of **2**. The downfield shifted C-1′ (Δ 3.8 ppm), C-2′ (Δ 4.1 ppm) and C-3′ (Δ 6.1 ppm) in comparison with the corresponding carbons of **2** further supported the methoxy substitution.

The molecular formula of spiromastol D (**4**) was determined as C~19~H~22~O~6~ based on the HRESIMS (*m/z* 345.1341 \[M − H\]^−^) and NMR data. The ^13^C NMR spectrum provided a total of 19 carbon resonances, including 12 aromatic carbons for two phenyl rings, a carboxylic carbon, and six alkyl carbons which were assigned to two *n*-propyl groups based on the COSY and HMBC data. The COSY spectrum displayed two aromatic spin systems of *meta*-couplings between δ~H~ 5.77 (1H, d, *J* = 2.3 Hz, H-3)/6.21(1H, d, *J* = 2.3 Hz, H-5) for ring A, and δ~H~ 6.27 (1H, d, *J* = 2.8 Hz, H-3′)/6.11 (1H, d, *J* = 2.8 Hz, H-5′) for ring B. In the aromatic ring A, the HMBC interactions from a phenol proton at δ~H~ 9.45 (s, OH-4) to C-3 (δ~C~ 98.7), C-4 (δ~C~ 158.8) and C-5 (δ~C~ 109.1) indicated C-4 to be hydroxylated. Additional HMBC interactions from H-5 to the methylene carbon at δ~C~ 35.5 and from H-3 and H-5 to C-1 (δ~C~ 115.7) and the carboxylic carbon at δ~C~ 169.5 through ^4^*J*~H-C~ coupling, revealed the position of a *n*-propyl group at C-6 (δ~C~ 141.9) and the carboxylic group at C-1. The oxygenated C-2 (δ~C~ 157.1) was assigned by the ^2^*J*~H-C~ coupling between H-3 and C-2 in the HMBC spectrum. The substitution of the second *n*-propyl group at C-6′ (δ~C~ 137.0) in the aromatic ring B was evident from the HMBC interaction between H-5′ and the methylene carbon at δ~C~ 32.0 (C-7′), while the NOE interactions between a phenol proton at δ~H~ 9.21 (s, OH-2′) and H-3′, and from the other phenol proton at δ~H~ 9.11 (s, OH-4′) to H-3′ and H-5′ assigned a 2′, 4′-dihydroxy-6′-propylphenyl ring. Since C-4 was positioned by a hydroxy group, the connection of the aromatic ring B at C-1′ (δ~C~ 132.6) with the aromatic ring A through an ether bond with C-2 or ester bond with C-10 was suggested. The observation of the carboxylic proton at δ~H~ 12.58 (brs) clarified C-10 to be an acidic group. Thus, the linkage of ring B with ring A though an ether bond across C-2 and C-1′ was assumed.

Spiromastol E (**5**) has a molecular formula of C~20~H~24~O~6~ as determined by the HRESIMS (*m/z* 359.1498 \[M − H\]^−^) and NMR data, bearing a CH~2~ unit more than that of **4**. Apart from **5** containing an additional methoxy group (δ~H~ 3.66, δ~C~ 56.0), the NMR data of both **5** and **4** were closely similar ([Table 1](#marinedrugs-13-02526-t001){ref-type="table"} and [Table 2](#marinedrugs-13-02526-t002){ref-type="table"}). The methoxy group of **5** was positioned at C-2′ (δ~C~ 153.2) on the basis of the HMBC relationship between the methoxy protons and C-2′. Thus, compound **5** was determined as a 2′-methoxylated analogue of **4**.

marinedrugs-13-02526-t001_Table 1

###### 

The ^1^H NMR data of spiromastols A--K (**1**--**11**) (δ~H~ ppm, *J* in Hz).

  No          1 ^a^           2 ^a^           3 ^b^           4 ^b^           5 ^b^           6 ^c^           7 ^b^                                        8 ^a^                                        9 ^b^           10 ^b^          11 ^a^
  ----------- --------------- --------------- --------------- --------------- --------------- --------------- -------------------------------------------- -------------------------------------------- --------------- --------------- ---------------
  1           5.97 s          5.97 s          6.00 s                                                                                                                                                                                    
  3                                                           5.77 (d, 2.3)   5.67 (d, 1.8)   6.05 s          5.90 brs                                     5.81 (d, 1.8)                                5.96 (d, 2.2)   6.59 (d, 1.9)   6.55 (d, 1.7)
  5                                                           6.21 (d, 2.3)   6.20 (d, 1.8)                   6.26 brs                                     6.26 (d, 1.8)                                6.35 (d, 2.2)   6.51 (d, 1.9)   6.47 (d, 1.7)
  7           2.48 m          2.49 m          2.51 m          2.51 (t, 6.5)   2.49 m          2.62 (t, 7.7)   2.77 (dd, 10.6, 16.2) 2.87 (dd, 2.7, 16.2)   2.77 (dd, 10.4, 16.0) 2.87 (dd, 2.5, 16.0)   6.32 s          2.61 m          2.65 (t, 7.5)
  8           1.40 m          1.39 m          1.41 m          1.56 m          1.56 m          1.55 m          4.50 m                                       4.51 m                                                       1.55 m          1.55 m
  9           0.81 (t, 7.2)   0.81 (t, 7.2)   0.81 (t, 7.3)   0.90 (t, 7.3)   0.90 (t, 7.2)   0.93 (t, 7.4)   1.37 (d, 6.3)                                1.37 (d, 6.3)                                2.42 (t, 7.3)   0.89 (t, 7.3)   0.89 (t, 7.5)
  10                                                                                                                                                                                                    1.63 m                          
  11                                                                                                                                                                                                    0.95 (t, 7.5)                   
  3′          6.57 s                                          6.27 (d, 2.8)   6.39 (d, 2.4)   6.26 (d, 2.7)   6.28 (d, 2.6)                                6.42 (d, 2.3)                                6.31 (d, 2.6)   6.25 (d, 1.7)   6.24 (d, 1.8)
  5′                                                          6.11 (d, 2.8)   6.25 (d, 2.4)   6.09 (d, 2.7)   6.14 (d, 2.6)                                6.28 (d, 2.3)                                6.15 (d, 2.6)   6.20 (d, 1.7)   6.19 (d, 1.8)
  7′          2.46 m          2.43 m          2.48 m          2.28 (t, 7.4)   2.30 (t, 7.6)   2.26 (t, 7.6)   2.27 (t, 7.6)                                2.28 m                                       2.26 (t, 7.6)   2.59 m          2.59 (t, 7.7)
  8′          1.39 m          1.38 m          1.40 m          1.40 m          1.40 m          1.38 m          1.45 m                                       1.43 m                                       1.46 m          1.55 m          1.56 m
  9′          0.82 (t, 7.2)   0.82 (t, 7.5)   0.83 (t, 7.3)   0.79 (t, 7.3)   0.78 (t, 7.4)   0.77 (t, 7.2)   0.78 (t, 7.4)                                0.77 (t, 7.5)                                0.77 (t, 7.4)   0.90 (t, 7.3)   0.90 (t, 7.3)
  1-COOH                                                      12.58 brs       12.37 brs       12.78 brs                                                                                                                 12.23 brs       12.20 brs
  2-OH                                                                                                                                                                                                                  9.87 s          
  4-OH        10.00 brs       10.10 s                         9.45 s          9.39 brs        10.10 s         10.20 s                                      10.22 s                                      10.46 s                         9.87 s
  2′-OH       9.73 s          9.91 s                          9.21 s                          9.33 brs        9.27 s                                                                                    9.37 s          10.14 s         10.14 s
  2′-OCH~3~                                   3.83 s                          3.66 s                                                                       3.65 s                                                                       
  4′-OH       9.99 s          9.86 s                          9.11 brs        9.34 brs        9.12 s          9.12 s                                       9.37 s                                       9.18 s          9.87 s          9.88 s

^a^ recorded in DMSO-*d*~6~ at 500 MHz; ^b^ recorded in DMSO-*d*~6~ at 400 MHz; ^c^ recorded in DMSO-*d*~6~ at 600 MHz.

marinedrugs-13-02526-t002_Table 2

###### 

^13^C NMR data of spiromastols A--K (**1**--**11**) (δ~C~ ppm).

  No          1 ^a^        2 ^a^          3 ^b^        4 ^b^        5 ^b^        6 ^c^        7 ^b^        8 ^a^        9 ^b^        10 ^b^       11 ^a^
  ----------- ------------ -------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------
  1           106.7 CH     106.8 CH       106.8 CH     115.7 C      115.9 C      116.4 C      105.0 C      104.7 C      100.8 C      113.6 CH     118.8 C
  2           153.1 C      152.9 C        152.5 C      157.1 C      156.9 C      153.9 C      162.4 C      162.4 C      158.3 C      157.4 C      158.3 C
  3           108.4 C      108.9 C        109.0 C      98.7 CH      98.3 CH      99.3 CH      100.6 CH     100.2 CH     100.7 CH     107.5 CH     107.5 CH
  4           150.3 C      150.5 C        150.6 C      158.8 C      158.7 C      154.2 C      162.8 C      162.8 C      164.2 C      152.2 C      152.2 C
  5           114.8 C      115.4 C        115.6 C      109.1 CH     108.9 CH     112.0 C      107.6 CH     107.7 CH     103.9 CH     119.1 C      113.5 CH
  6           139.0 C      139.3 C        139.5 C      141.9 C      141.7 C      137.9 C      144.1 C      144.2 C      141.9 C      143.1 C      143.5 C
  7           35.6 CH~2~   35.5 CH~2~     35.5 CH~2~   35.5 CH~2~   35.5 CH~2~   33.2 CH~2~   35.8 CH~2~   35.8 CH~2~   103.1 CH     35.9 CH~2~   36.1 CH~2~
  8           22.8 CH~2~   22.8 CH~2~     22.8 CH~2~   24.3 CH~2~   24.2 CH~2~   22.6 CH~2~   73.5 CH      73.5 CH      158.1 C      24.4 CH~2~   24.4 CH~2~
  9           13.8 CH~3~   13.8 CH~3~     13.8 CH~3~   14.2 CH~3~   14.4 CH~3~   14.2 CH~3~   20.9 CH~3~   20.9 CH~3~   34.8 CH~2~   14.3 CH~3~   14.3 CH~3~
  10                                                   169.5 C      169.2 C      168.4 C      168.5 C      168.5 C      20.1 CH~2~   170.2 C      170.4 C
  11                                                                                                                    13.8 CH~3~                
  12                                                                                                                    162.8 C                   
  1′          132.7 C      134.2 C        138.0 C      132.6 C      133.2 C      131.8 C      132.6 C      133.1 C      132.2 C      110.0 C      110.0 C
  2′          149.3 C      146.4 C        150.5 C      150.8 C      153.2 C      150.3 C      150.4 C      152.7 C      150.3 C      159.0 C      159.1 C
  3′          102.7 CH     109.6 C        115.7 C      102.0 CH     99.0 CH      101.6 CH     102.1 CH     99.1 CH      102.2 CH     101.0 CH     101.0 CH
  4′          151.5 C      148.0 C        147.0 C      155.2 C      155.5 C      154.9 C      155.3 C      155.7 C      155.4 C      160.9 C      160.9 C
  5′          110.4 C      112.8 C        118.8 C      107.4 CH     108.3 CH     106.9 CH     107.4 CH     108.3 CH     107.5 CH     108.9 CH     108.9 CH
  6′          134.6 C      132.7 C        133.5 C      137.0 C      137.0 C      136.4 C      136.5 C      136.8 C      136.3 C      144.2 C      144.2 C
  7′          30.1 CH~2~   30.1 CH~2~     30.1 CH~2~   32.0 CH~2~   31.8 CH~2~   31.5 CH~2~   32.2 CH~2~   32.0 CH~2~   32.2 CH~2~   36.3 CH~2~   36.4 CH~2~
  8′          22.3 CH~2~   22.1\` CH~2~   22.1 CH~2~   23.5 CH~2~   23.4 CH~2~   23.0 CH~2~   23.1 CH~2~   23.0 CH~2~   23.0 CH~2~   24.6 CH~2~   24.6 CH~2~
  9′          14.4 CH~3~   14.3 CH~3~     14.3 CH~3~   14.4 CH~3~   14.1 CH~3~   13.7 CH~3~   14.3 CH~3~   14.3 CH~3~   14.3 CH~3~   14.4 CH~3~   14.4 CH~3~
  10′                                                                                                                                167.3 C      167.4 C
  2′-OCH~3~                               60.8 CH~3~                56.0 CH~3~                             56.0 CH~3~                             

^a^ recorded in DMSO-*d*~6~ at 125 MHz; ^b^ recorded in DMSO-*d*~6~ at 100 MHz; ^c^ recorded in DMSO-*d*~6~ at 150 MHz.

The molecular formula of spiromastol F (**6**) was determined as C~19~H~21~ClO~6~ by the HRESIMS (*m/z* 379.0951 \[M − H\]^−^) and NMR data, with one chlorine atom more than that of **4**. Comparison of the NMR data revealed that both compounds had the same partial structure of the aromatic ring B, whereas a quaternary carbon at δ~C~ 112.0 (C-5) in the aromatic ring A of **6** was recognized to replace the aromatic methine C-5 of **4**. This finding reflected C-5 of **6** to be substituted by a chlorine atom. This assignment was supported by the HMBC correlations from H~2~-7 and OH-4′ (δ~H~ 10.10, s) to C-5, in association with the similar NMR data and HMBC relationships of the remaining resonances.

Spiromastol G (**7**) has a molecular formula of C~19~H~20~O~6~, as determined by the HRESIMS (*m/z* 343.1176 \[M − H\]^−^) and NMR data, requiring ten degrees of unsaturation. The NMR data of **7** regarding the aromatic ring B were compatible to those of **4**, indicating that both compounds share the same partial structure of ring B. The distinction was attributed to the substitution of the propyl group at C-6 of the aromatic ring A, in which the methyl protons (δ~H~ 1.37, d, *J* = 6.3 Hz, H~3~-9) showed a COSY correlation with an oxymethine proton (δ~H~ 4.50, m, H-8) and the HMBC interactions with C-8 (δ~C~ 73.5) and C-7 (δ~C~ 35.8). These facts indicated C-8 to be substituted by an oxygen atom. Additional HMBC interaction between H-8 and the carbonyl carbon at δ~C~ 168.5 (C-10) allowed the formation of a δ-lactone. Thus, ring A was assigned as a 8-methyldihydroisocoumarine unit. The HMBC interactions of phenol protons at δ~H~ 10.20 (1H, s, OH-4), 9.27 (1H, s, OH-2′) and 9.12 (1H, s, OH-4′) with the aromatic carbons allowed the assignment of C-4 (δ~C~ 162.8), C-2′ (δ~C~ 150.4) and C-4′ (δ~C~ 155.3) to be hydroxylated. Additional HMBC relationships from the aromatic protons to the aromatic carbons ([Figure 2](#marinedrugs-13-02526-f002){ref-type="fig"}) assigned C-2 (δ~C~ 162.4) and C-1′ (δ~C~ 132.6) to be substituted by oxygen atoms. The absence of phenol protons for OH-2 and OH-1′ conducted the connection of rings A and B through an ether bond across C-2/C-1′. Based on the helicity rule of the chiral benzoic ester chromophore \[[@B15-marinedrugs-13-02526],[@B16-marinedrugs-13-02526]\], the negative circular dichroism (CD) effect ([Figure 3](#marinedrugs-13-02526-f003){ref-type="fig"}) at 273 nm (Δε-1.23) for the n-π\* transition reflected 8*R* configuration.

![Circular dichroism (CD) curves of **7** and **8**.](marinedrugs-13-02526-g003){#marinedrugs-13-02526-f003}

Spiromastol H (**8**) has a molecular formula of C~20~H~22~O~6~ as provided by the HRESIMS (*m/z* 357.1338 \[M − H\]^−^) and NMR data, containing a CH~2~ unit more than that of **7**. The NMR data of both **8** and **7** were very similar, except for **8** presenting an additional methoxy group (δ~H~ 3.65, δ~C~ 56.0). These findings indicated **8** to be a methoxylated analogue of **7**. The HMBC relationship between the methoxy protons and C-2′ (δ~C~ 152.7) determined **8** as a 2′-methoxylated analogue of **7**. The similar CD effects \[Δε-1.84 (272)\] ([Figure 3](#marinedrugs-13-02526-f003){ref-type="fig"}) revealed the same configuration at C-8 of both compounds.

The molecular formula of spiromastol I (**9**) was established as C~21~H~22~O~6~ based on the HRESIMS (*m/z* 369.1339 \[M − H\]^−^) and NMR data, requiring 11 degrees of unsaturation. Comparison of the NMR data resulted in the partial structure regarding the aromatic ring B to be the same as that of **7**. Analysis of 1D and 2D NMR (COSY, HMQC and HMBC) data disclosed an isocoumarin core, based on the presence of *meta*-spin system at H-3 (δ~H~ 5.96, d, *J* = 2.2 Hz) and H-5 (δ~H~ 6.35, d, *J* = 2.2 Hz), in association with the HMBC interactions from H-5 to C-1 (δ~C~ 100.8), C-3 (δ~C~ 100.7), C-4 (δ~C~ 164.2), C-7 (δ~C~ 103.1) and C-12 (δ~C~ 162.8), H-3 to C-1, C-2 (δ~C~ 158.3), C-4, C-5 (δ~C~ 103.9) and C-12, H-7 (δ~H~ 6.32, s) to C-1, C-5, C-6 (δ~C~ 141.9), and C-9 (δ~C~34.8), as well as a phenol proton at δ~H~ 10.46 (s, OH-4) to C-3, C-4 and C-5. These findings ascertained C-4 to be hydroxylated, while C-2 was substituted by an oxygen atom. The COSY correlations afforded an additional *n*-propyl group, whose methylene protons at δ~H~ 2.42 (2H, t, *J* = 7.3 Hz, H~2~-9) showed the HMBC correlations with C-8 and C-7, indicating the *n*-propyl group to be positioned at C-8. Since the phenol protons OH-4, OH-2′ (δ~H~ 9.36, s) and OH-4′ (δ~H~ 9.18, s) were defined, the only possibility for the connection of isocoumarin moiety with the aromatic ring B through a C-2/C-1′ ether bond was determined.

Spiromastol J (**10**) had a molecular formula of C~20~H~22~O~7~ as determined by the HRESIMS (*m/z* 373.1287 \[M − H\]^−^) and NMR data. Analysis of the ^1^H and ^13^C NMR data revealed the presence of two aromatic rings, two *n*-propyl groups and two carboxylic carbons, while the HMQC spectrum assigned the protons and their associated carbons. In the COSY spectrum, two spin systems for *meta*-coupling aromatic protons between δ~H~ 6.59 (d, *J* = 1.9 Hz, H-3)/6.51 (d, *J* = 1.9 Hz, H-5) and δ~H~ 6.25 (d, *J* = 1.7 Hz, H-3′)/6.20 (d, *J* = 1.7 Hz, H-5′) were observed. The substitution of the *n*-propyl groups at C-6 (δ~C~ 143.1) and C-6′ (δ~C~ 144.2), respectively, was evident from the HMBC interactions between H-5/C-7 (δ~C~ 35.9) and H-5′/C-7′ (δ~C~ 36.3). A phenol proton at δ~H~ 10.14 (s) showed the HMBC correlations with C-1′ (δ~C~ 110.0), C-2′ (δ~C~ 159.0) and C-3′ (δ~C~ 101.0) assigned C-2′ to be hydroxylated. Although the absence of the HMBC interaction for remaining phenol protons due to their broad signals, the HMBC correlations of the aromatic protons enabled to assign C-2 (δ~C~ 157.4) and C-4 (δ~C~ 152.2) of the aromatic ring A, and C-4′ (δ~C~ 160.9) of the aromatic ring B to be oxygenated. The ^4^*J*~H-C~ correlations observed from H-3 and H-5 to the carboxylic carbon at δ~C~ 170.2 (C-10) and from H-3′ and H-5′ to δ~C~ 167.3 (C-10′) conducted the carboxylic groups to be located at C-1 and C-1′, respectively. In order to establish the connection of both aromatic rings A and B, compound **10** was methylated \[[@B17-marinedrugs-13-02526]\] to form an analogue **10a** ([Figure 4](#marinedrugs-13-02526-f004){ref-type="fig"}), which displayed four methoxy resonances in the ^1^H NMR spectrum. The HMBC interactions of **10a** between δ~H~ 3.92 (3H, s, OMe)/δ~C~ 168.5 (s, C-10), δ~H~ 3.85 (3H, s, OMe)/δ~C~ 157.3 (s, C-2), δ~H~ 3.86 (3H, s, OMe)/δ~C~ 158.6 (s, C-2′), and δ~H~ 3.89 (3H, s, OMe)/δ~C~ 161.9 (s, C-4′), clarified an ester bond formed across C-4 and C-10′.

Spiromastol K (**11**) has the same molecular formula as that of **10** as determined by the HRESIMS (*m/z* 373.1281 \[M − H\]^−^) data. The NMR data of both **11** and **10** were virtually similar. The presence of the phenol protons OH-2′ (δ~H~ 10.14, s) and OH-4′ (δ~H~ 9.88, s) in addition to their HMBC correlations with the aromatic carbons resulted in the partial structure regarding the aromatic ring B of **11** to be the same as that of **10**. A phenol proton at δ~H~ 9.87 (s) in ring A showing the HMBC interactions with C-3 (δ~C~ 107.5), C-4 (δ~C~ 152.2) and C-5 (δ~C~ 113.5) revealed C-4 to be hydroxylated. Thus, the connection of aromatic rings B with A through an ester bond across C-10′ (δ~C~ 167.4) and C-2 (δ~C~ 158.3) was assumed. The HMBC interactions of the methylated analogue **11a** ([Figure 4](#marinedrugs-13-02526-f004){ref-type="fig"}) further supported the structural assignment.

![Methylation of **10** and **11**.](marinedrugs-13-02526-g004){#marinedrugs-13-02526-f004}

Spiromastols (**1**--**11**) were tested against a panel of bacterial strains, including *Xanthomanes vesicatoria* ATCC 11633, *Pseudomonas lachrymans* ATCC11921, *Agrobacterium tumefaciens* ATCC11158, *Ralstonia solanacearum* ATCC11696, *Bacillus thuringensis* ATCC 10792, *Staphylococcus aureus* ATCC 25923 and *Bacillus subtilis* CMCC 63501. As shown in [Table 3](#marinedrugs-13-02526-t003){ref-type="table"}, compounds **1**--**3** exhibited potent antibacterial activities against all strains of bacteria with minimal inhibitory concentration (MIC) values ranging from 0.25 to 4 µg/mL, while compounds **9--11** showed moderate inhibition with MIC values in the range of 8--64 µg/mL. However, no inhibition was observed for compounds **4--8**. Analysis of the structure-activity relationships of spiromastols revealed that antibacterial activities depended on the substitution in rings A and B. The dichlorinated ring A (**1**--**3**) increased the inhibitory effects against bacteria, while the 2′-methoxylated analogue **3** showed more potent effect than that with a 2′-hydroxy group (**2**). The analogues with a carboxylic acid at C-1 (**4**--**6**) dramatically decreased the antibacterial activity. Comparison of the data of **7**--**9** ([Table 3](#marinedrugs-13-02526-t003){ref-type="table"}) revealed that isocoumarin **9** showed stronger inhibition than those with dihydroisocoumarin scaffold (**7**--**8**). The analogues with an ester bond connecting rings A and B (**10**--**11**) showed stronger effects than these with an ether bond (**4**--**6**). These data may help to design or modify new analogues with potential antibacterial effects.

marinedrugs-13-02526-t003_Table 3

###### 

Antibacterial activities of compounds **1**--**11**.

               MIC (µg/mL)                                           
  ------------ ------------- ------- ------- ------- ------- ------- -------
  **1**        0.5           0.5     0.25    0.5     0.5     0.25    0.5
  **2**        4             4       4       4       4       2       4
  **3**        0.25          0.5     0.5     0.5     0.5     0.5     0.5
  **4**        \>128         \>128   \>128   \>128   \>128   \>128   \>128
  **5**        \>128         \>128   \>128   \>128   \>128   \>128   \>128
  **6**        \>128         \>128   \>128   \>128   \>128   \>128   \>128
  **7**        \>128         \>128   \>128   \>128   \>128   \>128   \>128
  **8**        \>128         \>128   \>128   \>128   \>128   \>128   \>128
  **9**        8             8       8       8       16      8       16
  **10**       32            32      32      32      64      32      32
  **11**       32            32      32      32      64      32      32
  **CP** ^a^   1             1       1       2       2       2       2

CP ^a^: chloroamphenicol, positive control.

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

Optical rotations were measured on a Rudolph IV Autopol automatic polarimeter at 25 °C. UV spectra were measured on a Cary 300 spectrometer. IR spectra were measured on a Thermo Nicolet Nexus 470 FT-IR spectrometer. CD spectra were measured on a JASCO J-810 spectropolarimeter. ^1^H, ^13^C, and 2D NMR spectra were recorded on a Bruker Advance 400, 500, and 600 NMR spectrometers, respectively. Chemical shifts are expressed in δ (ppm) referenced to the solvent peaks at δ~H~ 2.50 and δ~C~ 39.5 for DMSO-*d*~6~, and δ~H~ 7.26 and δ~C~ 77.2 for CDCl~3~, respectively, and coupling constants are in Hz. HRESIMS spectra were obtained from Xevo G2 Q-TOF mass spectrometer. Materials for column chromatography (CC) involved silica gel (100--200 and 200--300 mesh, Qingdao Marine Chemistry Co. Ltd., Qingdao, China), ODS gel (50 μm, YMC, Japan) and Sephadex LH-20 (18--110 μm, Amersham Pharmacia Biotech AB, Uppsala, Sweden). Precoated silica gel plates (Merck, Kieselgel 60 F254, 0.25 mm) were used for TLC analysis. HPLC chromatography was performed on a Waters e2695 separation Module coupled with a Waters 2998 photodiode array detector and a semi-preparative reversed-phased column (YMC-packed C~18~, 5 μm, 250 mm × 10 mm) was used for purification.

3.2. Fungal Material and Fermentation
-------------------------------------

The fungal *Spiromastix* sp. MCCC 3A00308 was isolated from a deep ocean sediment, which was collected with TV-multicore in June 2011 from the South Atlantic Ocean at site S015-TVMC06 (GPS 13.75° W, 15.17° S) at a depth of 2869 m during the Comra 22nd oceanic cruise Leg 5. The fungus was identified as *Spiromastix* genus by ITS gene sequence analysis (GeneBank accession number KJ010057). The strain MCCC 3A00308 was deposited in the Marine Culture Collection Center (MCCC), Third Institute of Oceanography, State Oceanic Administration, Xiamen, China. The fungus *Spiromastix* sp. MCCC 3A00308 was cultured on PDA slants at 25 °C for 10 days. The fermentation was carried out in Erlenmeyer flasks (50 × 500 mL), each containing 100 g of rice, to which distilled H~2~O (140 mL) was added. The contents were soaked overnight before autoclaving at 15 psi for 30 min. After cooling to about 30 °C, each flask was inoculated with 5 mL of the spore inoculum and incubated at 25 °C for 50 days.

3.3. Extraction and Isolation
-----------------------------

The fermentation broth of *Spiromastix* sp. MCCC 3A00308 fungus was extracted three times with ethyl acetate (3 × 10 L). The organic extracts were evaporated under vacuum to afford crude extracts (58.4 g). The crude extract was subjected to silica gel vacuum liquid chromatography (VLC) eluted with petroleum ether--Me~2~CO (50:1--1:1) to afford 10 fractions (FA--FJ). FG (6.1 g) was purified through an ODS column eluted with MeOH-H~2~O (1:1--1:0) to give eleven sub-fractions (SFG1--SFG11). SFG9 (165 mg) was separated sequentially on ODS column eluted with MeOH--H~2~O (1:1--1:0), and semi-preparative HPLC with a mobile phase of MeCN-H~2~O (4:1) to yield compound **3** (3.8 mg). FH (8.2 g) was separated by ODS chromatography eluted with MeOH--H~2~O (1:1--1:0) to obtain ten sub-fractions (SFH1--SFH10). SFH5 (423 mg) was purified by silica gel column eluted with petroleum ether-acetone (10:1) and then by semi-preparative HPLC with a mobile phase of MeCN--H~2~O (11:9) to obtain **6** (1.2 mg), while compounds **9** (6.5 mg), **11** (4.1 mg), and **10** (18.7 mg) were separated from SFH4 (120 mg) by the same protocol as for SFH5. SFH6 (72 mg) was subjected to a Sephadex LH-20 column eluting with MeOH to afford compound **1** (4.6 mg). SFH7 (1.1 g) was purified by an ODS column eluted with MeOH--H~2~O (2:3--1:0), and then by semi-preparative HPLC with a mobile phase of MeCN-H~2~O (33:17) to obtain **2** (2.0 mg). FI (2.7 g) was separated by ODS chromatography eluted with MeOH-H~2~O (1:1--1:0) to obtain twenty-eight sub-fractions (SFI1--SFI28). SFI20 (168 mg) was separated by a Sephadex LH-20 column eluted with MeOH to collect three fractions (SFI20-1 to SFI20-3). The semi-preparative HPLC separation of SFI20-1 (28 mg) with a mobile phase of MeCN-H~2~O (11:9) to yield compounds **5** (3.5 mg) and **8** (1.6 mg), while compounds **7** (5.0 mg) and **4** (22.3 mg) were obtained from SFI20-2 (46 mg) by the same protocol as for SFI20-1.

Spiromastol A (**1**): Colorless oil; UV (MeOH) λ~max~ (logε) 215 (4.48), 288 (3.71); IR (KBr) ν~max~ 3408, 2962, 2871, 1651, 1601, 1459, 1242, 1154 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-13-02526-t001){ref-type="table"} and [Table 2](#marinedrugs-13-02526-t002){ref-type="table"}; HRESIMS *m/z* 403.0272 \[M − H\]^−^ (calcd for C~18~H~18~O~4~Cl~3~, 403.0271).

Spiromastol B (**2**): Colorless oil; UV (MeOH) λ~max~ (logε) 213 (4.42), 288 (3.54); IR (KBr) ν~max~ 3450, 2961, 2930, 2870, 1716, 1580, 1442, 1335, 1227, 1180 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-13-02526-t001){ref-type="table"} and [Table 2](#marinedrugs-13-02526-t002){ref-type="table"}; HRESIMS *m/z* 436.9873 \[M − H\]^−^ (calcd for C~18~H~17~O~4~Cl~4~, 436.9881).

Spiromastol C (**3**): Colorless oil; UV (MeOH) λ~max~ (logε) 215 (4.59), 288 (3.46); IR (KBr) ν~max~ 3360, 2960, 2933, 2870, 1655, 1581, 1461, 1419, 1313, 1246, 1198 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-13-02526-t001){ref-type="table"} and [Table 2](#marinedrugs-13-02526-t002){ref-type="table"}; HRESIMS *m/z* 451.0042 \[M − H\]^−^ (calcd for C~19~H~19~O~4~Cl~4~, 451.0037).

Spiromastol D (**4**): Colorless oil; UV (MeOH) λ~max~ (logε) 213 (4.37), 282 (3.67); IR (KBr) ν~max~ 3276, 2961, 2930, 2870, 1705, 1605, 1459, 1317, 1239, 1193 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-13-02526-t001){ref-type="table"} and [Table 2](#marinedrugs-13-02526-t002){ref-type="table"}; HRESIMS *m/z* 345.1341 \[M − H\]^−^ (calcd for C~19~H~21~O~6~, 345.1338).

Spiromastol E (**5**): Colorless oil; UV (MeOH) λ~max~ (logε) 208 (4.19), 279 (3.46); IR (KBr) ν~max~ 3281, 2959, 2930, 2870, 1705, 1604, 1458, 1321, 1251, 1195 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-13-02526-t001){ref-type="table"} and [Table 2](#marinedrugs-13-02526-t002){ref-type="table"}; HRESIMS *m/z* 359.1498 \[M − H\]^−^ (calcd for C~20~H~23~O~6~, 359.1495).

Spiromastol F (**6**): Colorless oil; UV (MeOH) λ~max~ (logε) 215 (4.26), 282 (3.52); IR (KBr) ν~max~ 3306, 2961, 2931, 2871, 1701, 1607, 1458, 1364, 1231, 1196 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-13-02526-t001){ref-type="table"} and [Table 2](#marinedrugs-13-02526-t002){ref-type="table"}; HRESIMS *m/z* 379.0951 \[M − H\]^−^ (calcd for C~19~H~20~O~6~Cl, 379.0948).

Spiromastol G (**7**): Colorless oil; $\left\lbrack \text{α} \right\rbrack_{\text{D}}^{25}$ −4 (*c* = 0.2, MeOH); UV (MeOH) λ~max~ (logε) 206 (4.27), 227 (4.25), 266 (3.98), 292 (3.64); IR (KBr) ν~max~ 3349, 2960, 2928, 2869, 1676, 1608, 1464, 1340, 1257, 1186, 1158 cm^−1^; CD (MeOH) λ (Δε) 301 (−1.06), 291 (−1.02), 273 (−1.23), 259 (0.30), 238 (−3.47), 215 (7.38). ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-13-02526-t001){ref-type="table"} and [Table 2](#marinedrugs-13-02526-t002){ref-type="table"}; HRESIMS *m/z* 343.1176 \[M − H\]^−^ (calcd for C~19~H~19~O~6~, 343.1182).

Spiromastol H (**8**): Colorless oil; $\left\lbrack \text{α} \right\rbrack_{\text{D}}^{25}$ −6 (*c* 0.2, MeOH); UV (MeOH) λ~max~ (logε) 205 (4.16), 226 (4.02), 265 (3.81), 292 (3.51); IR (KBr) ν~max~ 3358, 2961, 2930, 2870, 1688, 1607, 1463, 1337, 1249, 1193 cm^−1^; CD (MeOH) λ (Δε) 301 (−1.06), 291 (−0.75), 272 (−1.84), 257 (−0.11), 243 (−0.47), 213 (4.12). ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-13-02526-t001){ref-type="table"} and [Table 2](#marinedrugs-13-02526-t002){ref-type="table"}; HRESIMS *m/z* 357.1338 \[M − H\]^−^ (calcd for C~20~H~21~O~6~, 357.1338).

Spiromastol I (**9**): Colorless oil; UV (MeOH) λ~max~ (logε) 207 (4.26), 245 (4.60), 278 (3.88), 321 (3.64); IR (KBr) ν~max~ 3246, 2960, 2871, 1689, 1597, 1461, 1359 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-13-02526-t001){ref-type="table"} and [Table 2](#marinedrugs-13-02526-t002){ref-type="table"}; HRESIMS *m/z* 369.1339 \[M − H\]^−^ (calcd for C~21~H~21~O~6~, 369.1338).

Spiromastol J (**10**): Colorless oil; UV (MeOH) λ~max~ (logε) 216 (4.41), 270 (4.13), 301 (3.92); IR (KBr) ν~max~ 3396, 2960, 2872, 1656, 1614, 1451, 1311, 1248, 1192 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-13-02526-t001){ref-type="table"} and [Table 2](#marinedrugs-13-02526-t002){ref-type="table"}; HRESIMS *m/z* 373.1287 \[M − H\]^−^ (calcd for C~20~H~21~O~7~, 373.1287).

Spiromastol K (**11**): Colorless oil; UV (MeOH) λ~max~ (logε) 216 (4.32), 270 (4.04), 300 (3.85); IR (KBr) ν~max~ 3163, 2959, 2870, 1654, 1591, 1453, 1310, 1248, 1195 cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-13-02526-t001){ref-type="table"} and [Table 2](#marinedrugs-13-02526-t002){ref-type="table"}; HRESIMS *m/z* 373.1281 \[M − H\]^−^ (calcd for C~20~H~21~O~7~, 373.1287).

3.4. Methylation
----------------

Compound **10** (5.0 mg) was dissolved in anhydrous acetone (900 µL), and then K~2~CO~3~ (3.8 mg) and CH~3~I (650 μL) were added to the solution, which was stirred for 16 h at 0 °C. After filtration, the solution was concentrated *in vacuo*, and the residue was purified on a silica gel column eluting with petroleum ether-Me~2~CO (20: 1) to obtain the methyl ether **10a** (2.9 mg, 58% yield). Compound **11** is submitted to the same protocol as for **10** to derive a methylated product **11a**.

Compound **10a**: ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 6.72 (1H, d, *J* = 1.8, H-3), 6.68 (1H, d, *J* = 1.8, H-5), 6.41 (1H, d, *J* = 2.1, H-5′), 6.39 (1H, d, *J* = 2.1, H-3′), 3.92 (3H, s, OMe-10), 3.89 (3H, s, OMe-2′), 3.86 (3H, s, OMe-4′), 3.85 (3H, s, OMe-2), 2.70 (2H, t, *J* = 7.8, H~2~-7′), 2.58 (2H, t, *J* = 7.9, H~2~-7), 1.72 (2H, m, H~2~-8′), 1.65 (2H, m, H~2~-8), 1.00 (3H, t, *J* = 7.3, H~3~-9′), 0.97 (3H, t, *J* = 7.4, H~3~-9); ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 168.5 (C-10), 166.4 (C-10′), 161.9 (C-4′), 158.6 (C-2′), 157.3 (C-4), 152.5 (C-2), 143.5 (C-6′), 142.4 (C-6), 121.1 (C-5), 115.2 (C-1′), 114.4 (C-1), 106.1 (C-5′), 102.7 (C-3), 96.3 (C-3′), 56.1 (OMe-2′), 56.0 (OMe-2), 55.4 (OMe-4′), 52.2 (OMe-10), 36.1 (C-7′), 35.6 (C-7), 24.6 (C-8′), 24.0 (C-8), 14.1 (C-9′), 14.0 (C-9). ESIMS *m/z* 431.32 \[M + H\]^+^, 453.26 \[M + Na\]^+^.

Compound **11a**: ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 6.70 (1H, d, *J* = 2.0, H-3), 6.66 (1H, d, *J* = 2.0, H-5), 6.40 (1H, d, *J* = 2.0, H-5′), 6.38 (1H, d, *J* = 2.0, H-3′), 3.92 (3H, s, OMe-10), 3.87 (3H, s, OMe-2′), 3.86 (3H, s, OMe-4′), 3.82 (3H, s, OMe-4), 2.71 (2H, t, *J* = 7.8, H~2~-7′), 2.56 (2H, t, *J* = 7.9, H~2~-7), 1.71 (2H, m, H~2~-8′), 1.67 (2H, m, H~2~-8), 1.01 (3H, t, *J* = 7.0, H~3~-9′), 0.96 (3H, t, *J* = 7.0, H~3~-9); ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 168.3 (C-10), 166.5 (C-10′), 161.8 (C-4′), 158.5 (C-2′), 157.8 (C-4), 152.3 (C-2), 143.4 (C-6′), 142.5 (C-6), 119.0 (C-5), 115.3 (C-1′), 114.2 (C-1), 106.0 (C-5′), 102.2 (C-3), 96.4 (C-3′), 56.2 (OMe-2′), 56.1 (OMe-4), 55.3 (OMe-4′), 52.1 (OMe-10), 36.0 (C-7′), 35.5 (C-7), 24.7 (C-8′), 24.4 (C-8), 14.0 (C-9′), 14.1 (C-9). ESIMS *m/z* 431.30 \[M + H\]^+^.

3.5. Antibacterial Assay
------------------------

Spiromastols A--K (**1**--**11**) were tested against a panel of seven bacterial strains, including *Xanthomanes vesicatoria* ATCC 11633, *Pseudomonas lachrymans* ATCC11921, *Agrobacterium tumefaciens* ATCC11158, *Ralstonia solanacearum* ATCC11696, *Bacillus thuringensis* ATCC 10792, *Staphylococcus aureus* ATCC 25923 and *Bacillus subtilis* CMCC 63501, according to previously described methods \[[@B14-marinedrugs-13-02526]\].

4. Conclusions
==============

In summary, this work described a group of new polyphenols with diverse scaffolds derived from deep sea derived fungus *Spiromastix* sp., while these findings provided additional evidence to support that the microorganisms from deep sea are a potential source for the discovery of chemical diversity. The potent antibacterial effects of **1**--**3** suggested that these compounds can be used for further lead modification.
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